// App-Quantinova.ai

3044 : SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus.

Researchers

Presenter

  • Lucia Nogova

Principal Investigators

  • Matthias Scheffler

  • Deniz Kahraman

  • Carsten Kobe

  • Kerstin Rhiem

  • Peter Mallmann

  • Roland Schnell

  • Ildiko Katay

  • Max Schlaak

  • Markus Dietlein

  • Juergen Wolf

  • Marc Christiaan Allardt Bos

  • Masyar Gardizi

  • Irini Papachristou

  • Noemi Muthen

  • Denis Rokitta

  • Martina Kinzig

  • Fritz Soergel

  • Uwe Fuhr

Medical Centers

  • Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany

  • Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany

  • Center of Familial Breast and Ovarian Cancer, Department of Gynecology and Obstetrics, University Hospital Cologne, Cologne, Germany

  • Institute for Biomedical and Pharmaceutical Research, Nuernberg-Heroldsberg, Germany

  • University of Cologne, Cologne, DE, Germany

  • Praxis fuer Haematologie und Internistische Onkologie, Cologne, Germany

  • Institut fuer Pharmakologie, University Cologne, Cologne, Germany

  • University Hospital of Cologne, Department of Nuclear Medicine, Cologne, Germany

  • Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany

  • Pioh, private practice for hematology and oncology, Frechen/Cologne, Germany, Cologne, Germany

  • Department of Dermatology, University Hospital, Cologne, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Everolimus

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved